Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Zoll Medical AED Plus

This article was originally published in The Gray Sheet

Executive Summary

Automated external defibrillator shipments are expected to begin this summer following 510(k) clearance, announced March 26. Zoll's first offering for the public access defibrillator market, the device incorporates Rectilinear Biphasic waveform technology and also is the first AED to feature a single electrode pad and run on off-the-shelf batteries, according to Zoll. A patent infringement suit filed by competitor Cardiac Science March 28 in California federal court relates to Cardiac Science's '919 and '299 patents for electrode packaging and sensor technology, and seeks an injunction on sales and unspecified damages. Zoll says it is "confident that the AED Plus does not infringe these patents"...

You may also be interested in...

Zoll Seeks To Move Blood, AED Market With New CPR Device

Future automated external defibrillator market growth will be augmented by complementary technology developed to aid in other aspects of cardiopulmonary resuscitation, Zoll Medical President and CEO Richard Packer believes

Cardiac Science v. Zoll Medical

Settlement of patent infringement lawsuit includes cross-licensing of a number of patents related to automated public access defibrillators. In addition, Cardiac Science will receive an undisclosed initial licensing fee and ongoing royalties. The lawsuit involved Cardiac Science's '919 and '299 patents for electrode packaging and sensor technology and was filed March 28 in California federal court 1("The Gray Sheet" April 1, 2002, In Brief)...

QUOTED. 1 December. Rob Field.

UK start-up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country. See what Iceni’s CEO Rob Field said about it here.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts